These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23740824)

  • 21. A Prospective Evaluation of the Effects of Prevalent Depressive Symptoms on Disease Activity in Rheumatoid Arthritis Patients Treated With Biologic Response Modifiers.
    Rathbun AM; Harrold LR; Reed GW
    Clin Ther; 2016 Jul; 38(7):1759-1772.e3. PubMed ID: 27368116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
    Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
    J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes and sex differences in patient reported outcomes in rheumatoid factor positive RA-results from a community based study.
    Hekmat K; Jacobsson LT; Nilsson JÅ; Lindroth Y; Turesson C
    BMC Musculoskelet Disord; 2014 Feb; 15():44. PubMed ID: 24552546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-reported outcomes as predictors of remission in early rheumatoid arthritis patients treated with tight control treat-to-target approach.
    Kuusalo L; Puolakka K; Kautiainen H; Karjalainen A; Malmi T; Yli-Kerttula T; Leirisalo-Repo M; Rantalaiho V;
    Rheumatol Int; 2017 May; 37(5):825-830. PubMed ID: 28289873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world study.
    Pope JE; Rampakakis E; Sampalis J
    Semin Arthritis Rheum; 2015 Apr; 44(5):499-505. PubMed ID: 25440158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
    Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry.
    Furst DE; Pangan AL; Harrold LR; Chang H; Reed G; Kremer JM; Greenberg JD
    Arthritis Care Res (Hoboken); 2011 Jun; 63(6):856-64. PubMed ID: 21337725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry.
    Kavanaugh A; Keystone E; Greenberg JD; Reed GW; Griffith JM; Friedman AW; Saunders KC; Ganguli A
    Rheumatology (Oxford); 2017 Jul; 56(7):1095-1101. PubMed ID: 28340006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.
    Miwa Y; Saito M; Furuya H; Yanai R; Ikari Y; Hayashi T; Kasama T; Toyoshima Y; Inagaki K
    Intern Med; 2017 Sep; 56(17):2271-2275. PubMed ID: 28794381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE).
    Sugihara T; Ishizaki T; Hosoya T; Iga S; Yokoyama W; Hirano F; Miyasaka N; Harigai M
    Rheumatology (Oxford); 2015 May; 54(5):798-807. PubMed ID: 25296748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept.
    Bessette L; Haraoui B; Rampakakis E; Dembowy J; Trépanier MO; Pope J
    Arthritis Res Ther; 2023 Sep; 25(1):183. PubMed ID: 37759330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treat-to-target in rheumatoid arthritis: Evaluating the patient perspective using the Patient Opinion Real-Time Anonymous Liaison system: The RA T2T PORTAL study.
    Benham H; Rutherford M; Kirby S; Stebbings S; White D; Sim D; Harrison A
    Int J Rheum Dis; 2019 May; 22(5):874-879. PubMed ID: 30793870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis.
    Fautrel B; Alten R; Kirkham B; de la Torre I; Durand F; Barry J; Holzkaemper T; Fakhouri W; Taylor PC
    Rheumatol Int; 2018 Jun; 38(6):935-947. PubMed ID: 29564549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treat-to-target and shared decision making in rheumatoid arthritis treatment: Is it feasible?
    Falzer PR
    Int J Rheum Dis; 2019 Sep; 22(9):1706-1713. PubMed ID: 31359630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of 17 Definitions of Remission with Functional Status in a Large Clinical Practice Cohort of Patients with Rheumatoid Arthritis.
    Carvalho PD; Ferreira RJO; Landewé R; Vega-Morales D; Salomon-Escoto K; Veale DJ; Chopra A; da Silva JAP; Machado PM
    J Rheumatol; 2020 Jan; 47(1):20-27. PubMed ID: 31043552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in the activity of rheumatoid arthritis as the consequence of treat-to-target strategy: eight-year data from 2009 to 2016.
    Xie W; Li J; Zhang X; Li G; Hao Y; Zhao J; Wang L; Sun X; Fan Y; Zhang Z
    Clin Exp Rheumatol; 2018; 36(5):820-828. PubMed ID: 29533754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment and management of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2009 Jun; 82():2-10. PubMed ID: 19509324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values.
    Chung MK; Park B; Kim IJ; Cho SK; Kim D; Sung YK; Choi CB; Choe JY; Chung WT; Hong SJ; Kim TH; Koh E; Lee SS; Yoon BY; Park H; Bae SC; Lee J
    Int J Rheum Dis; 2019 May; 22(5):852-859. PubMed ID: 30677239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register.
    Twigg S; Hensor EMA; Emery P; Tennant A; Morgan AW;
    J Rheumatol; 2017 Sep; 44(9):1331-1340. PubMed ID: 28668806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of rheumatoid arthritis in Turkey: a questionnaire study.
    Direskeneli H; Akkoç N; Bes C; Cakir N; Cefle A; Cobankara V; Dalkilic E; Dinc A; Ertenli I; Gul A; Hamuryudan V; Inanc M; Kalyoncu U; Karaaslan Y; Kasifoglu T; Keser G; Keskin G; Kisacik B; Kiraz S; Masatlioglu S; Onat AM; Ozbek S; Ozturk MA; Pamuk ON; Pay S; Pirildar T; Sayarlioglu M; Senel S; Senturk T; Tasan D; Terzioglu E; Yazici A; Yucel E
    Clin Exp Rheumatol; 2014; 32(4):477-83. PubMed ID: 24960289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.